JP2013536244A - Ｅｇｆｒ阻害剤の投与方法 - Google Patents

Ｅｇｆｒ阻害剤の投与方法 Download PDF

Info

Publication number
JP2013536244A
JP2013536244A JP2013526123A JP2013526123A JP2013536244A JP 2013536244 A JP2013536244 A JP 2013536244A JP 2013526123 A JP2013526123 A JP 2013526123A JP 2013526123 A JP2013526123 A JP 2013526123A JP 2013536244 A JP2013536244 A JP 2013536244A
Authority
JP
Japan
Prior art keywords
treatment
patient
egfr inhibitor
egfr
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013526123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536244A5 (Direct
Inventor
ロバート マイケル ローレンス
メディ シャヒディ
ペーター シュトップファー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013536244(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2013536244A publication Critical patent/JP2013536244A/ja
Publication of JP2013536244A5 publication Critical patent/JP2013536244A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
JP2013526123A 2010-08-26 2011-08-24 Ｅｇｆｒ阻害剤の投与方法 Pending JP2013536244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37717710P 2010-08-26 2010-08-26
US61/377,177 2010-08-26
PCT/US2011/048922 WO2012027445A1 (en) 2010-08-26 2011-08-24 Methods of administering an egfr inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016252456A Division JP6541637B2 (ja) 2010-08-26 2016-12-27 Ｅｇｆｒ阻害剤の投与方法

Publications (2)

Publication Number Publication Date
JP2013536244A true JP2013536244A (ja) 2013-09-19
JP2013536244A5 JP2013536244A5 (Direct) 2014-10-09

Family

ID=44583460

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013526123A Pending JP2013536244A (ja) 2010-08-26 2011-08-24 Ｅｇｆｒ阻害剤の投与方法
JP2016252456A Active JP6541637B2 (ja) 2010-08-26 2016-12-27 Ｅｇｆｒ阻害剤の投与方法
JP2019079787A Pending JP2019147814A (ja) 2010-08-26 2019-04-19 Ｅｇｆｒ阻害剤の投与方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016252456A Active JP6541637B2 (ja) 2010-08-26 2016-12-27 Ｅｇｆｒ阻害剤の投与方法
JP2019079787A Pending JP2019147814A (ja) 2010-08-26 2019-04-19 Ｅｇｆｒ阻害剤の投与方法

Country Status (16)

Country Link
US (2) US20130289056A1 (Direct)
EP (1) EP2608792B1 (Direct)
JP (3) JP2013536244A (Direct)
CY (1) CY1119898T1 (Direct)
DK (1) DK2608792T3 (Direct)
EC (1) ECSP13012523A (Direct)
ES (1) ES2655115T3 (Direct)
HR (1) HRP20180016T1 (Direct)
HU (1) HUE038049T2 (Direct)
LT (1) LT2608792T (Direct)
NO (1) NO2608792T3 (Direct)
PL (1) PL2608792T3 (Direct)
PT (1) PT2608792T (Direct)
RS (1) RS56682B1 (Direct)
SI (1) SI2608792T1 (Direct)
WO (1) WO2012027445A1 (Direct)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2770308T3 (es) 2008-10-02 2020-07-01 Salix Pharmaceuticals Ltd Procedimientos de tratamiento de encefalopatía hepática
NO2608792T3 (Direct) 2010-08-26 2018-03-10
BR112021010500A2 (pt) * 2018-11-30 2021-08-24 Beth Israel Deaconess Medical Center, Inc. Método para reduzir a p-selectina solúvel em um paciente com câncer, método para reduzir ou prevenir a formação de um trombo em um paciente com câncer, método para promover a regressão tumoral em um paciente com câncer, método para estabilizar ou reduzir o câncer metastático em um paciente com câncer, composição farmacêutica para reduzir a p-selectina solúvel em um paciente com câncer, composição farmacêutica para reduzir ou prevenir a formação de um trombo em um paciente com câncer, composição farmacêutica para promover a regressão tumoral em um paciente com câncer e composição farmacêutica para estabilizar ou reduzir câncer metastático em um paciente com câncer
US12403122B2 (en) 2021-05-19 2025-09-02 Quercis Pharma AG Method for treating amyotrophic lateral sclerosis using quercetin-containing compositions
WO2023288044A1 (en) 2021-07-16 2023-01-19 Beth Israel Deaconess Medical Center, Inc. Method for treating sickle cell disease using quercetin-containing compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2002087585A1 (en) * 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20070009533A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
WO2007054550A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
DK1948180T3 (da) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
EP1981863B1 (en) 2006-01-26 2012-10-10 Boehringer Ingelheim International GmbH Process for preparing aminocrotonylamino-substituted quinazoline derivatives
NZ576065A (en) 2006-09-18 2011-12-22 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
NO2608792T3 (Direct) 2010-08-26 2018-03-10

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6015028185; Ｖａｎ　Ｅｒｐ，　Ｎ．　Ｐ．　ｅｔ　ａｌ．，　Ｃａｎｃｅｒ　Ｔｒｅａｔ．　Ｒｅｖ．，　２００９，　ｖｏｌ．３５，　ｎｏ．８，　ｐ．６９２-７０６ *
JPN6015028186; Ｓｗａｉｓｌａｎｄ，　Ｈ．　Ｃ．　ｅｔ　ａｌ．，Ｃｌｉｎ．　Ｐｈａｒｍａｃｏｋｉｎｅｔ．　２００５，　ｖｏｌ．４４，　ｎｏ．１０，　ｐ．１０６７-８１ *
JPN6015028188; Ｃｈｈｕｎ，　Ｓ．　ｅｔ　ａｌ．，　Ｂｒ．　Ｊ．　Ｃｌｉｎ．　Ｐｈａｒｍａｃｏｌ．，　２００９，　ｖｏｌ．６８，　ｎｏ．２，　ｐ．２２６-３７ *
JPN6015028189; Ａｇａｒｗａｌ，　Ｓ．　ｅｔ　ａｌ．，　Ｊ．　Ｐｈａｒｍａｃｏｌ．　Ｅｘｐ．　Ｔｈｅｒ．，　２０１０　Ｊｕｌ，　ｖｏｌ．３３４，　ｎｏ．１，　ｐ．１４７-５５ *
JPN6015028190; Ｃｏｌｌｉｎｓ，　Ｄ．　Ｍ．，　Ｉｎｖｅｓｔ．　Ｎｅｗ　Ｄｒｕｇｓ，　２０１０　Ａｕｇ，　Ｅｐｕｂ　２００９　Ｊｕｎ，　ｖｏｌ．２８，　ｎｏ．４，　ｐ．４３３-４４ *
JPN6015028191; Ｓｈｉ，　Ｚ．　ｅｔ　ａｌ．，　Ｂｉｏｃｈｅｍ．　Ｐｈａｒｍａｃｏｌ．，　２００９，　ｖｏｌ．７７，　ｎｏ．５，　ｐ．７８１-９３ *
JPN6015028192; Ｍｉｎｌｏｖｓｋｙ，　Ｎ．　ｅｔ　ａｌ．，　Ｃｕｒｒｅｎｔ　Ｏｐｉｎｉｏｎ　ｉｎ　Ｉｎｖｅｓｔｉｇａｔｉｏｎａｌ　Ｄｒｕｇｓ，　２００８，　ｖｏｌ．９，　ｎｏ．１２，　ｐ．１３３６-４６ *

Also Published As

Publication number Publication date
HUE038049T2 (hu) 2018-09-28
ECSP13012523A (es) 2013-05-31
JP2017081966A (ja) 2017-05-18
HRP20180016T1 (hr) 2018-02-09
NO2608792T3 (Direct) 2018-03-10
SI2608792T1 (en) 2018-02-28
JP6541637B2 (ja) 2019-07-10
LT2608792T (lt) 2018-01-10
CY1119898T1 (el) 2018-06-27
WO2012027445A1 (en) 2012-03-01
EP2608792A1 (en) 2013-07-03
DK2608792T3 (en) 2018-01-15
RS56682B1 (sr) 2018-03-30
US20160287591A1 (en) 2016-10-06
ES2655115T3 (es) 2018-02-16
JP2019147814A (ja) 2019-09-05
PL2608792T3 (pl) 2018-03-30
US20130289056A1 (en) 2013-10-31
EP2608792B1 (en) 2017-10-11
PT2608792T (pt) 2018-01-15

Similar Documents

Publication Publication Date Title
JP2019147814A (ja) Ｅｇｆｒ阻害剤の投与方法
EP2068880B1 (en) Method for treating cancer harboring egfr mutations
JP5688877B2 (ja) 癌疾患の治療用キナゾリン誘導体
EP1948180B1 (en) Combination treatment of cancer comprising egfr/her2 inhibitors
EP3120851A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US20230056604A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024216200A1 (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
EA045102B1 (ru) Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170308